vTv Therapeutics (NASDAQ:VTVT) Releases Earnings Results, Beats Expectations By $0.15 EPS

vTv Therapeutics (NASDAQ:VTVT) released its earnings results on Thursday. The biotechnology company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.15, FiscalAI reports.

vTv Therapeutics Trading Down 9.5%

Shares of VTVT stock opened at $21.74 on Friday. The company’s 50-day moving average price is $29.46 and its 200-day moving average price is $33.29. The stock has a market cap of $85.66 million, a price-to-earnings ratio of -20.51 and a beta of 0.28. vTv Therapeutics has a twelve month low of $21.72 and a twelve month high of $44.00.

Wall Street Analyst Weigh In

VTVT has been the subject of several recent research reports. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. BTIG Research reaffirmed a “buy” rating and set a $57.00 target price on shares of vTv Therapeutics in a report on Wednesday, October 14th. Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Wall Street Zen downgraded shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Finally, HC Wainwright dropped their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, vTv Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $55.83.

About vTv Therapeutics

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.